ARTICLE | Clinical News

AZ's olaparib leads to responses in CRPC

October 29, 2015 2:41 AM UTC

Data published Wednesday in the New England Journal of Medicine showed olaparib ( AZD2281) from AstraZeneca plc (LSE:AZN; NYSE:AZN) led to a response in 33% of patients in the Phase II TOPARP-A study to treat castration-resistant prostate cancer, including higher response rates in patients with mutations in DNA repair genes.

AZ markets the poly(ADP-ribose) polymerase ( PARP) inhibitor as Lynparza to treat ovarian cancer in patients with BRCA mutations. The pharma provided support for the study, which was led by the U.K.'s Institute of Cancer Research (ICR) and the Royal Marsden NHS Foundation Trust. ...